Please check your internet connection and try again.
# Linagliptin
## Overview
Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin hormone concentrations, stimulating glucose-dependent insulin release and decreasing glucagon levels. Unlike other DPP-4 inhibitors, it is primarily excreted via the biliary/gastrointestinal route rather than the kidneys.
## Primary Indications
Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
## Adult Dosing
Standard dose: 5 mg orally once daily.
Maximum dose: 5 mg daily.
## Pediatric Dosing
Safety and effectiveness in pediatric patients (under 18 years) have not been established. Use is generally not recommended.
## Dose Adjustments
* **Renal Impairment:** No dose adjustment required.
* **Hepatic Impairment:** No dose adjustment required.
## Contraindications
* History of hypersensitivity reaction to linagliptin (e.g., anaphylaxis, angioedema, exfoliative skin conditions).
* Type 1 diabetes or treatment of diabetic ketoacidosis.
## Adverse Effects
* **Common:** Nasopharyngitis, hypoglycemia (when used with insulin or secretagogues).
* **Serious:** Acute pancreatitis, severe arthralgia (joint pain), bullous pemphigoid, hypersensitivity reactions (urticaria, angioedema).
## Key Drug Interactions
* **CYP3A4/P-gp Inducers:** Strong inducers (e.g., rifampin, carbamazepine, phenytoin) may decrease linagliptin efficacy. If co-administration is necessary, monitor glycemic control closely.
* **Insulin/Sulfonylureas:** Risk of hypoglycemia is additive; a reduction in the insulin or insulin secretagogue dose may be required.
## Monitoring
* **Baseline/Routine:** HbA1c (typically every 3–6 months), periodic assessment of renal function (though not required for dosing).
* **Clinical:** Monitor for signs/symptoms of pancreatitis (persistent severe abdominal pain) and bullous pemphigoid (blistering or erosions).
## Clinical Pearls
* **Unique Excretion:** Linagliptin is the only DPP-4 inhibitor that does not require renal dose adjustments, making it a preferred choice in patients with chronic kidney disease.
* **Administration:** May be taken with or without food.
* **Weight Neutral:** Generally considered weight-neutral compared to other antidiabetic agents.
* **Pancreatitis Risk:** Discontinue promptly if pancreatitis is suspected. If confirmed, do not resume.
***
*Disclaimer: This information is for educational purposes only. Clinical practice guidelines and drug labeling may change. Always verify current prescribing information, institutional protocols, and patient-specific factors before administering any medication.*
